646 related articles for article (PubMed ID: 37033156)
1. Targeted protein degradation in cancers: Orthodox PROTACs and beyond.
Li J; Chen X; Lu A; Liang C
Innovation (Camb); 2023 May; 4(3):100413. PubMed ID: 37033156
[TBL] [Abstract][Full Text] [Related]
2. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
[TBL] [Abstract][Full Text] [Related]
3. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques.
Chen S; Cui J; Chen H; Yu B; Long S
Eur J Med Chem; 2023 Dec; 262():115911. PubMed ID: 37924709
[TBL] [Abstract][Full Text] [Related]
5. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
6. Advancing targeted protein degradation for metabolic diseases therapy.
Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
[TBL] [Abstract][Full Text] [Related]
7. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD).
Wang H; Zhou R; Xu F; Yang K; Zheng L; Zhao P; Shi G; Dai L; Xu C; Yu L; Li Z; Wang J; Wang J
Biomater Res; 2023 Jul; 27(1):72. PubMed ID: 37480049
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
9. Novel approaches to targeted protein degradation technologies in drug discovery.
Xue Y; Bolinger AA; Zhou J
Expert Opin Drug Discov; 2023 Apr; 18(4):467-483. PubMed ID: 36895136
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in targeted protein degraders as potential therapeutic agents.
Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
[TBL] [Abstract][Full Text] [Related]
11. PROTACs in gastrointestinal cancers.
Chen Y; Yang Q; Xu J; Tang L; Zhang Y; Du F; Zhao Y; Wu X; Li M; Shen J; Ding R; Cao H; Li W; Li X; Chen M; Wu Z; Cho CH; Du Y; Wen Q; Xiao Z
Mol Ther Oncolytics; 2022 Dec; 27():204-223. PubMed ID: 36420306
[TBL] [Abstract][Full Text] [Related]
12. Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy.
Fang Y; Wang J; Zhao M; Zheng Q; Ren C; Wang Y; Zhang J
J Med Chem; 2022 Sep; 65(17):11454-11477. PubMed ID: 36006861
[TBL] [Abstract][Full Text] [Related]
13. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation.
Ruffilli C; Roth S; Rodrigo M; Boyd H; Zelcer N; Moreau K
ACS Pharmacol Transl Sci; 2022 Oct; 5(10):849-858. PubMed ID: 36268122
[TBL] [Abstract][Full Text] [Related]
15. Degraders upgraded: the rise of PROTACs in hematological malignancies.
Casan JML; Seymour JF
Blood; 2024 Mar; 143(13):1218-1230. PubMed ID: 38170175
[TBL] [Abstract][Full Text] [Related]
16. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
Tamatam R; Shin D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
[TBL] [Abstract][Full Text] [Related]
17. Targeted protein degradation: A promise for undruggable proteins.
Samarasinghe KTG; Crews CM
Cell Chem Biol; 2021 Jul; 28(7):934-951. PubMed ID: 34004187
[TBL] [Abstract][Full Text] [Related]
18. Target and tissue selectivity of PROTAC degraders.
Guenette RG; Yang SW; Min J; Pei B; Potts PR
Chem Soc Rev; 2022 Jul; 51(14):5740-5756. PubMed ID: 35587208
[TBL] [Abstract][Full Text] [Related]
19. Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery.
Espinoza-Chávez RM; Salerno A; Liuzzi A; Ilari A; Milelli A; Uliassi E; Bolognesi ML
ACS Bio Med Chem Au; 2023 Feb; 3(1):32-45. PubMed ID: 37101607
[TBL] [Abstract][Full Text] [Related]
20. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
Nalawansha DA; Crews CM
Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]